Sign In
Buy FDMT
$11.60
+1.18 (+11.32%)
At Close: Jun 23, 2026
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
10:45am, Tuesday, 23'rd Jun 2026
4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 12'th Jun 2026
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
12:22am, Wednesday, 10'th Jun 2026
4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
05:52pm, Friday, 05'th Jun 2026
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
4DMT to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 27'th May 2026
EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
06:30pm, Friday, 22'nd May 2026
4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
08:03pm, Saturday, 16'th May 2026
4D Molecular Therapeutics NASDAQ: FDMT executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage devel
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 15'th May 2026
EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
07:40pm, Wednesday, 13'th May 2026
4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
08:11pm, Thursday, 07'th May 2026
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to a loss of $0.86 per share a year ago.
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
04:05pm, Thursday, 07'th May 2026
EMERYVILLE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4DMT to Participate in Upcoming Investor Conferences
08:00am, Monday, 04'th May 2026
EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 17'th Apr 2026
EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
4D Molecular Therapeutics (NASDAQ:FDMT) versus TransCode Therapeutics (NASDAQ:RNAZ) Head-To-Head Contrast
01:33am, Friday, 03'rd Apr 2026
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will co
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.
03:33am, Tuesday, 31'st Mar 2026
Assenagon Asset Management S.A. decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) by 55.4% in the fourth quarter, according to its most recent 13F filing with the Securities and
